search for




 

Case Report
Two Cases of Adjuvant Immunotherapy with Cytokine-Induced Killer Cells for Relapsed or Refractory Neuroblastoma
Clin Pediatr Hematol Oncol 2018;25:202-7.
Published online October 31, 2018
© 2018 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Jung Yoon Choi, M.D., Hong Yul An, M.D., Kyung Taek Hong, M.D., Chery Hong, M.D., Hyoung Jin Kang, M.D. and Hee Young Shin, M.D.

Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul, Korea
Correspondence to: Hee Young Shin
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children’s Hospital, Seoul National University Cancer Research Institute, 101, Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-2917
Fax: +82-2-743-3455
E-mail: hyshin@snu.ac.kr
ORCID ID: orcid.org/0000-0003-2091-1947
Received September 21, 2018; Revised September 30, 2018; Accepted October 15, 2018.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The treatment outcomes of relapsed or refractory neuroblastoma have been unsatisfactory till date. We reported two cases of adoptive immunotherapy using cytokine-induced killer (CIK) cells against relapsed or refractory neuroblastoma. CIK cell production was attempted in three patients, out of which two patients exhibited adequate levels of CIK cell production. Two patients completed full term of CIK cell infusions (weekly for 6 weeks and then biweekly for 8 wk) without serious adverse events. The progression- free survivals for the two patients were 1.9 and 4.1 months. Their overall survivals were 16.7 and 28.7 months. Although the efficacy was unclear, CIK cell infusion combined with other treatment strategies may have prolonged overall survival in refractory neuroblastoma patients. Further studies are needed to determine the exact role of CIK cell-based immunotherapy in relapsed or refractory neuroblastoma patients.
Keywords: Neuroblastoma, Refractory, Cytokine-induced killer cells


October 2018, 25 (2)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Hee Young Shin